beta-lysylmethanediamine: from Streptomyces nashvillensis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65021 |
| SCHEMBL ID | 2038493 |
| MeSH ID | M0139877 |
| Synonym |
|---|
| beta-lysylmethanediamine |
| 3,6-diamino-n-(aminomethyl)hexanamide |
| hexanamide, n-(aminomethyl)-3,6-diamino-, (r)- |
| d-beta-lysylmethanediamine |
| (r)-n-(aminomethyl)-3,6-diaminohexanamide |
| (3r)-3,6-diamino-n-(aminomethyl)hexanamide |
| d-.beta.-lysylmethanediamine |
| (r)-3,6-diamino-n-(aminomethyl)hexanamide |
| bellenamine |
| 102674-90-8 |
| l-bellenamine |
| (l)-3,6-diamino-n-(aminomethyl)hexanamide |
| SCHEMBL2038493 |
| DTXSID40145449 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.76) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||